Interleukin-17 inhibitors in myasthenia gravis: really bad or maybe good?

Neurol Sci. 2023 Aug;44(8):2981-2982. doi: 10.1007/s10072-023-06796-8. Epub 2023 Apr 11.

Authors

Sohyeon Kim^#¹, Mi-Yeon Eun^#², Hung Youl Seok³

Affiliations

¹ Department of Neurology, Dongsan Hospital, Keimyung University School of Medicine, 1035 Dalgubeol-Daero, Dalseo-Gu, Daegu, 42601, Korea.
² Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea.
³ Department of Neurology, Dongsan Hospital, Keimyung University School of Medicine, 1035 Dalgubeol-Daero, Dalseo-Gu, Daegu, 42601, Korea. shy2354@gmail.com.

^# Contributed equally.

PMID: 37041395
DOI: 10.1007/s10072-023-06796-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Cholinesterase Inhibitors
Humans
Interleukin Inhibitors
Interleukin-17*
Myasthenia Gravis* / drug therapy

Substances

Interleukin-17
Interleukin Inhibitors
Cholinesterase Inhibitors